Virtu Financial LLC Takes Position in Inotiv, Inc. (NASDAQ:NOTV)

Virtu Financial LLC purchased a new position in shares of Inotiv, Inc. (NASDAQ:NOTV) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,330 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned approximately 0.07% of Inotiv as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of NOTV. Vantage Point Financial LLC acquired a new stake in Inotiv in the 4th quarter valued at $1,393,000. Nkcfo LLC acquired a new stake in Inotiv during the fourth quarter worth about $476,000. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Inotiv by 612.5% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock valued at $527,000 after buying an additional 109,397 shares during the period. Calamos Advisors LLC purchased a new stake in Inotiv in the fourth quarter valued at $275,000. Finally, AlphaCentric Advisors LLC acquired a new position in Inotiv in the fourth quarter valued at about $163,000. 18.17% of the stock is owned by hedge funds and other institutional investors.

Inotiv Stock Performance

NASDAQ:NOTV opened at $2.21 on Tuesday. Inotiv, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $11.20. The company has a 50 day moving average price of $3.48 and a 200 day moving average price of $3.22. The stock has a market capitalization of $74.52 million, a P/E ratio of -0.48 and a beta of 3.77. The company has a debt-to-equity ratio of 2.31, a quick ratio of 1.28 and a current ratio of 1.57.

Inotiv (NASDAQ:NOTV) last posted its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. Equities research analysts forecast that Inotiv, Inc. will post -0.79 EPS for the current year.

Insider Buying and Selling at Inotiv

In other Inotiv news, CEO Robert Jr. Leasure sold 73,617 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.82, for a total value of $281,216.94. Following the sale, the chief executive officer now directly owns 956,592 shares in the company, valued at $3,654,181.44. This trade represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 108,311 shares of company stock valued at $425,330 in the last quarter. Corporate insiders own 7.80% of the company’s stock.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.